MedPath

A study to compare steroid versus N-acetyl cysteine to reduce complication after liver tumor directed vascular treatment

Phase 3
Conditions
Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Registration Number
CTRI/2024/03/063853
Lead Sponsor
AIIMS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All consecutive patients presenting to the Liver Clinic of the Department of Gastroenterology

and Human Nutrition, with cirrhosis and HCC in BCLC stages A-C who are being considered for

TACE will be screened for inclusion and will be included after informed consent

Exclusion Criteria

1. Allergy to contrast media

2. Main portal vein tumor thrombosis (PVTT)-VP4

3. Extrahepatic disease extension of HCC

4. Child Turcotte Pugh score greater than 9

5. Renal failure

6. Those already on steroids for any other disease e.g. autoimmune hepatitis

7. Active bacterial infection at the time of randomization

8. Bilirubin greater than 3 mg per dL

9. Pregnancy

10. Age less than 18 years

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome will be the proportion of patients developing PES in both groups. PES will be defined as presence of pain and or fever with an increase in the alanine aminotransferase <br/ ><br>(ALT) greater than 3X baseline value within 48 hrs after the procedureTimepoint: 48 hrs
Secondary Outcome Measures
NameTimeMethod
The secondary outcomes will be the proportions of patients developing PTD in both groups. <br/ ><br>Any development of new or worsening ascites, encephalopathy, gastrointestinal bleeding and <br/ ><br>increase in bilirubin by 2 mg per dL within one week of TACE. The proportion of patients with fever, nausea, vomiting, pain, ALT greater than 3X baseline will also be compared among both groups. Any side effects or complications related to the intervention used will also be reported.Timepoint: 7 days
© Copyright 2025. All Rights Reserved by MedPath